<DOC>
	<DOCNO>NCT00934973</DOCNO>
	<brief_summary>Background : Irritable bowel syndrome ( IBS ) affect 10-22 % United Kingdom ( UK ) population , National Health Service ( NHS ) cost £200 million year . Abdominal pain , bloat alter bowel habit affect quality life , social functioning time work . Current general practitioner ( GP ) treatment relies positive diagnosis , reassurance , lifestyle advice drug therapy , many suffer ongoing symptom . A recent Cochrane review highlight lack research evidence IBS drug . Neither GPs , patient good evidence inform prescribing decision . However , IBS drug widely use : NHS cost 2005 nearly £10 million mebeverine £8 million fiber-based bulking agent . Cognitive behavioral therapy ( CBT ) self-management helpful , poor availability NHS restrict use . Development web-based CBT could increase access without increased cost . Aims : 1 . To pilot randomize , control trial ( RCT ) ass effectiveness commonly prescribe medication UK general practice IBS : mebeverine ( anti-spasmodic ) methylcellulose ( bulking-agent ) patient CBT base self-management website . 2 . To assess level support need patient use patient CBT base self-management website IBS ( i.e. , initial 30 minute telephone support session nurse email support ) . Plan Investigation : 135 patient age 16-60 year IBS symptoms fulfil Rome III criterion , recruit via GP practice , randomise : mebeverine , methylcellulose placebo 6 week CBT base website nurse telephone session email support , website minimal support , website , thus create 9 group . Outcomes : Irritable bowel symptom severity scale IBS-QOL measure baseline , 6 12 week . An intention treat analysis undertaken analysis covariance ( ANCOVA ) factorial trial . Potential Impact : Development web-based self-management CBT program IBS develop partnership patient potential benefit large number patient low cost NHS . CBT show benefit IBS 's availability limit due high cost therapist time require face-to-face CBT . A website accessed time place convenient patient CBT program undertaken pace determine patient need . The website could use long term support self-management . Determining effectiveness commonly use drug treatment help patient doctor make informed treatment decision regard drug management IBS symptom , enable well target treatment may benefit .</brief_summary>
	<brief_title>Management Irritable Bowel Syndrome Primary Care ( MIBS Trial )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Mebeverine</mesh_term>
	<mesh_term>Alverine</mesh_term>
	<criteria>Patients age 16 60 year symptoms irritable bowel syndrome fulfill Rome III criterion Atypical symptom ( unexplained weight loss , rectal bleeding ) Diagnosis inflammatory bowel disease , coeliac disease peptic ulcer disease Pregnant breast feed Currently take allergy mebeverine methylcellulose</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>irritable bowel syndrome</keyword>
	<keyword>treatment</keyword>
</DOC>